Hyperglycaemia is associated with impaired pulsatile insulin secretion

Effect of basal insulin therapy

J. J. Meier, C. Pennartz, N. Schenker, B. A. Menge, W. E. Schmidt, T. Heise, C. Kapitza, Johannes D Veldhuis

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aim: Postprandial insulin pulsatility is impaired in patients with type 2 diabetes, but the effects of exogenous insulin therapy on pulsatile insulin secretion are not known. We addressed, whether pulsatile insulin secretion is related to glycaemic control, whether basal insulin supplementation increases postprandial insulin secretion, and if so, is this accomplished by a specific improvement in pulsatile insulin secretion? Methods: Fourteen patients with type 2 diabetes underwent a mixed meal test before and after an 8-week treatment period with insulin glargine. Glucose, insulin and C-peptide levels were measured, and insulin pulsatility was determined by deconvolution analysis. Results: Insulin treatment lowered fasting glycaemia from 179.6±7.5mg/dl to 117.6±6.5mg/dl (p<0.001). Postprandial insulin and C-peptide levels increased significantly after the treatment period (p<0.0001). The total calculated insulin secretion rate increased with insulin treatment (p=0.0039), with non-significant increases in both pulsatile and non-pulsatile insulin secretion. Insulin pulse frequency was unchanged by the intervention. There was an inverse relationship between fasting and postprandial glycaemia and insulin pulse mass (r2=0.51 and 0.56, respectively), whereas non-pulsatile insulin secretion was unrelated to either fasting or postprandial glucose concentrations (r2=0.0073 and 0.031). Conclusions: Hyperglycaemia in type 2 diabetes is associated with a reduction in postprandial insulin secretion, specifically through a reduction in insulin pulsatility. Reducing chronic hyperglycaemia by basal insulin therapy enhances endogenous β-cell function in the postprandial state. These data support the use of basal insulin regimens in the pharmacotherapy of overtly hyperglycaemic patients with type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)258-263
Number of pages6
JournalDiabetes, Obesity and Metabolism
Volume15
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Hyperglycemia
Insulin
Therapeutics
Type 2 Diabetes Mellitus
Fasting
C-Peptide
Glucose

Keywords

  • β-cell
  • Insulin therapy

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Meier, J. J., Pennartz, C., Schenker, N., Menge, B. A., Schmidt, W. E., Heise, T., ... Veldhuis, J. D. (2013). Hyperglycaemia is associated with impaired pulsatile insulin secretion: Effect of basal insulin therapy. Diabetes, Obesity and Metabolism, 15(3), 258-263. https://doi.org/10.1111/dom.12022

Hyperglycaemia is associated with impaired pulsatile insulin secretion : Effect of basal insulin therapy. / Meier, J. J.; Pennartz, C.; Schenker, N.; Menge, B. A.; Schmidt, W. E.; Heise, T.; Kapitza, C.; Veldhuis, Johannes D.

In: Diabetes, Obesity and Metabolism, Vol. 15, No. 3, 03.2013, p. 258-263.

Research output: Contribution to journalArticle

Meier, JJ, Pennartz, C, Schenker, N, Menge, BA, Schmidt, WE, Heise, T, Kapitza, C & Veldhuis, JD 2013, 'Hyperglycaemia is associated with impaired pulsatile insulin secretion: Effect of basal insulin therapy', Diabetes, Obesity and Metabolism, vol. 15, no. 3, pp. 258-263. https://doi.org/10.1111/dom.12022
Meier, J. J. ; Pennartz, C. ; Schenker, N. ; Menge, B. A. ; Schmidt, W. E. ; Heise, T. ; Kapitza, C. ; Veldhuis, Johannes D. / Hyperglycaemia is associated with impaired pulsatile insulin secretion : Effect of basal insulin therapy. In: Diabetes, Obesity and Metabolism. 2013 ; Vol. 15, No. 3. pp. 258-263.
@article{d00aa246c40e429c90ac40ad46b2c8c8,
title = "Hyperglycaemia is associated with impaired pulsatile insulin secretion: Effect of basal insulin therapy",
abstract = "Aim: Postprandial insulin pulsatility is impaired in patients with type 2 diabetes, but the effects of exogenous insulin therapy on pulsatile insulin secretion are not known. We addressed, whether pulsatile insulin secretion is related to glycaemic control, whether basal insulin supplementation increases postprandial insulin secretion, and if so, is this accomplished by a specific improvement in pulsatile insulin secretion? Methods: Fourteen patients with type 2 diabetes underwent a mixed meal test before and after an 8-week treatment period with insulin glargine. Glucose, insulin and C-peptide levels were measured, and insulin pulsatility was determined by deconvolution analysis. Results: Insulin treatment lowered fasting glycaemia from 179.6±7.5mg/dl to 117.6±6.5mg/dl (p<0.001). Postprandial insulin and C-peptide levels increased significantly after the treatment period (p<0.0001). The total calculated insulin secretion rate increased with insulin treatment (p=0.0039), with non-significant increases in both pulsatile and non-pulsatile insulin secretion. Insulin pulse frequency was unchanged by the intervention. There was an inverse relationship between fasting and postprandial glycaemia and insulin pulse mass (r2=0.51 and 0.56, respectively), whereas non-pulsatile insulin secretion was unrelated to either fasting or postprandial glucose concentrations (r2=0.0073 and 0.031). Conclusions: Hyperglycaemia in type 2 diabetes is associated with a reduction in postprandial insulin secretion, specifically through a reduction in insulin pulsatility. Reducing chronic hyperglycaemia by basal insulin therapy enhances endogenous β-cell function in the postprandial state. These data support the use of basal insulin regimens in the pharmacotherapy of overtly hyperglycaemic patients with type 2 diabetes.",
keywords = "β-cell, Insulin therapy",
author = "Meier, {J. J.} and C. Pennartz and N. Schenker and Menge, {B. A.} and Schmidt, {W. E.} and T. Heise and C. Kapitza and Veldhuis, {Johannes D}",
year = "2013",
month = "3",
doi = "10.1111/dom.12022",
language = "English (US)",
volume = "15",
pages = "258--263",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Hyperglycaemia is associated with impaired pulsatile insulin secretion

T2 - Effect of basal insulin therapy

AU - Meier, J. J.

AU - Pennartz, C.

AU - Schenker, N.

AU - Menge, B. A.

AU - Schmidt, W. E.

AU - Heise, T.

AU - Kapitza, C.

AU - Veldhuis, Johannes D

PY - 2013/3

Y1 - 2013/3

N2 - Aim: Postprandial insulin pulsatility is impaired in patients with type 2 diabetes, but the effects of exogenous insulin therapy on pulsatile insulin secretion are not known. We addressed, whether pulsatile insulin secretion is related to glycaemic control, whether basal insulin supplementation increases postprandial insulin secretion, and if so, is this accomplished by a specific improvement in pulsatile insulin secretion? Methods: Fourteen patients with type 2 diabetes underwent a mixed meal test before and after an 8-week treatment period with insulin glargine. Glucose, insulin and C-peptide levels were measured, and insulin pulsatility was determined by deconvolution analysis. Results: Insulin treatment lowered fasting glycaemia from 179.6±7.5mg/dl to 117.6±6.5mg/dl (p<0.001). Postprandial insulin and C-peptide levels increased significantly after the treatment period (p<0.0001). The total calculated insulin secretion rate increased with insulin treatment (p=0.0039), with non-significant increases in both pulsatile and non-pulsatile insulin secretion. Insulin pulse frequency was unchanged by the intervention. There was an inverse relationship between fasting and postprandial glycaemia and insulin pulse mass (r2=0.51 and 0.56, respectively), whereas non-pulsatile insulin secretion was unrelated to either fasting or postprandial glucose concentrations (r2=0.0073 and 0.031). Conclusions: Hyperglycaemia in type 2 diabetes is associated with a reduction in postprandial insulin secretion, specifically through a reduction in insulin pulsatility. Reducing chronic hyperglycaemia by basal insulin therapy enhances endogenous β-cell function in the postprandial state. These data support the use of basal insulin regimens in the pharmacotherapy of overtly hyperglycaemic patients with type 2 diabetes.

AB - Aim: Postprandial insulin pulsatility is impaired in patients with type 2 diabetes, but the effects of exogenous insulin therapy on pulsatile insulin secretion are not known. We addressed, whether pulsatile insulin secretion is related to glycaemic control, whether basal insulin supplementation increases postprandial insulin secretion, and if so, is this accomplished by a specific improvement in pulsatile insulin secretion? Methods: Fourteen patients with type 2 diabetes underwent a mixed meal test before and after an 8-week treatment period with insulin glargine. Glucose, insulin and C-peptide levels were measured, and insulin pulsatility was determined by deconvolution analysis. Results: Insulin treatment lowered fasting glycaemia from 179.6±7.5mg/dl to 117.6±6.5mg/dl (p<0.001). Postprandial insulin and C-peptide levels increased significantly after the treatment period (p<0.0001). The total calculated insulin secretion rate increased with insulin treatment (p=0.0039), with non-significant increases in both pulsatile and non-pulsatile insulin secretion. Insulin pulse frequency was unchanged by the intervention. There was an inverse relationship between fasting and postprandial glycaemia and insulin pulse mass (r2=0.51 and 0.56, respectively), whereas non-pulsatile insulin secretion was unrelated to either fasting or postprandial glucose concentrations (r2=0.0073 and 0.031). Conclusions: Hyperglycaemia in type 2 diabetes is associated with a reduction in postprandial insulin secretion, specifically through a reduction in insulin pulsatility. Reducing chronic hyperglycaemia by basal insulin therapy enhances endogenous β-cell function in the postprandial state. These data support the use of basal insulin regimens in the pharmacotherapy of overtly hyperglycaemic patients with type 2 diabetes.

KW - β-cell

KW - Insulin therapy

UR - http://www.scopus.com/inward/record.url?scp=84873845567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873845567&partnerID=8YFLogxK

U2 - 10.1111/dom.12022

DO - 10.1111/dom.12022

M3 - Article

VL - 15

SP - 258

EP - 263

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 3

ER -